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Cross-sectional studies suggest an increasing trend in in-
cidence and relatively low recurrence rates of Clostridium 
difficile infections in Asia than in Europe and North America. 
The temporal trend of C. difficile infection in Asia is not com-
pletely understood. We conducted a territory-wide popula-
tion-based observational study to investigate the burden 
and clinical outcomes in Hong Kong, China, over a 9-year 
period. A total of 15,753 cases were identified, includ-
ing 14,402 (91.4%) healthcare-associated cases and 817 
(5.1%) community-associated cases. After adjustment for di-
agnostic test, we found that incidence increased from 15.41 
cases/100,000 persons in 2006 to 36.31 cases/100,000 
persons in 2014, an annual increase of 26%. This increase 
was associated with elderly patients, for whom incidence 
increased 3-fold over the period. Recurrence at 60 days in-
creased from 5.7% in 2006 to 9.1% in 2014 (p<0.001). Our 
data suggest the need for further surveillance, especially in 
Asia, which contains ≈60% of the world’s population.
Clostridium difficile infection (CDI) is a major cause of nosocomial illness worldwide. CDI is associated with 
high rates of mortality and illness (1) and has a case-fatality 
rate of up to 14% within 30 days after diagnosis (2). Disease 
recurrence further increases illness rates, reduces quality of 
life, and might occur in up to 27% of the incident cases (3). 
These features place a major burden on healthcare systems.
The disease burden of CDI has been well studied in 
Europe and North America. Although antimicrobial drug 
stewardship programs have contributed to a decrease in in-
cidence in some countries, such as the United Kingdom and 
Finland (2,4), CDI is still a major health burden in other 
countries. In South Korea, a nationwide study showed an 
increasing trend in incidence of CDI (5). Disease occur-
rence in the United States has doubled during 2001–2010 
(6). A similar trend of increase was also observed in a pro-
spective surveillance study in Australia (7) and a retrospec-
tive observational study in Germany (8).
Emergence of community-associated CDI (CA-CDI), 
which originates in a community without traditional risk 
factors (9), is also a concern. A major proportion of CDI 
cases was attributable to a community in the United States 
(1). In Finland, episodes of CA-CDI have shown a major 
increase versus an overall decrease in disease incidence (2). 
Surveillance of CDI cases diagnosed during admission of 
patients showed that up to 50% of CDI cases were com-
munity associated (3,7).
Although Asia contains ≈60% of the world’s popula-
tion, epidemiologic data of CDI for this continent are sparse 
(10). The disease burden and secular trend of incidence, 
especially CA-CDI, has not been reported for this region. 
Therefore, we conducted a large territory-wide study to in-
vestigate the disease burden and clinical outcomes of CDI 
in Hong Kong, China.
Methods
Study Population and Case Identification
We identified all patients in Hong Kong given a diagno-
sis of CDI during January 1, 2006–December 31, 2014, 
from the Clinical Data Analysis and Reporting System 
(CDARS), which is a computerized database of patient 
records managed by the Hong Kong Hospital Authority. 
The database contains laboratory and clinical information, 
including patient demographics, disease diagnoses, inves-
tigations, procedures, and drug prescription records in the 
public hospital system. It also contains information regard-
ing residence in homes for elderly persons and medical 
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care provided by the Community Geriatric Assessment 
Team in the ambulatory care setting. This public hospital 
system is composed of 41 hospitals within 7 service clus-
ters and provides >90% of inpatient medical services in the 
territory. There were >1 million inpatient discharges and 
deaths in this system during 2013–2014. In addition to the 
ward-based services, the system also provides the outpa-
tient clinics and geriatric ambulatory care in Hong Kong. 
This electronic database has been used for conducting ro-
bust population studies (11,12).
We defined a case of CDI as a positive result on cul-
ture, toxin, or molecular assay for a diarrheal stool speci-
men obtained from an inpatient resident >18 years of age. 
Patients with samples obtained >48 hours after admission 
or those who were hospitalized in a healthcare facility with-
in the previous 4 weeks were classified as having cases of 
healthcare-associated CDI (HA-CDI). Patients who had not 
been hospitalized in a healthcare facility within the previ-
ous 12 weeks were classified as having cases of CA-CDI. 
Patients who had been hospitalized in a healthcare facility 
(including long-term care facilities, such as homes for el-
derly persons and palliative care centers) within the previ-
ous 4–12 weeks were classified as indeterminate. We de-
fined an incident case as a CDI episode without a positive 
laboratory test result in the previous 60 days.
Data Extraction
We obtained anonymized clinical information, includ-
ing patient demographics, disease diagnoses, laboratory 
results, and clinical outcomes. Patient demographic data 
included age, sex, and residence in homes for elderly per-
sons. Relevant disease diagnoses were identified by using 
codes from the International Classification of Diseases, 9th 
Revision (https://www.cdc.gov/nchs/icd/icd9.htm), includ-
ing inflammatory bowel disease (555._–556._), Crohn’s 
disease (555._), ulcerative colitis (556._), colectomy (45.7 
or 45.71–45.79), or surgical intervention during the same 
admission, and other concurrent conditions.
We retrieved data on medication prescriptions, in-
cluding antimicrobial drug use within 8 weeks before CDI 
diagnosis. Medications prescribed under hospital author-
ity–affiliated clinics and long-term care facilities were ac-
cessible in the database. Severe CDI was defined by either 
a maximum leukocyte count >15,000 cells/µL or a >50% 
increase in serum creatinine level, according to Cohen et 
al. (13). These data were captured from CDARS from 1 
day before to 7 days after the CDI diagnosis date. Re-
fractory disease referred to nonresponding disease requir-
ing >14 days of continued treatment. We defined death 
as dying within 30 days after the diagnosis of CDI and 
recurrence as a recurrent diarrheal stool specimen with 
a positive test result for C. difficile within 60 days after 
completion of CDI treatment.
Statistical Analysis
We reported descriptive statistics as median, interquartile 
range (IQR), and percentage and calculated the overall 
crude incidence of CDI as the number of patients given a 
diagnosis of CDI/100,000 persons >18 years of age. The 
midyear population was obtained from Hong Kong Census 
and Statistics Department.
We also estimated incidences of health-associated and 
community-associated cases in the same manner. We used 
the χ2 test for trend to compare differences in incidences, 
mortality rates, and recurrence rates. Assuming a Poisson 
distribution, we calculated 95% CIs for the incidence rate. 
We analyzed potential predictors for 30-day mortality rate 
and 60-day recurrence rate by using univariate and mul-
tivariate forward Wald logistic regression. We used Cox 
proportional hazard regression to identify factors that de-
creased the time to recurrence after an episode. We also 
used SPSS for Windows version 22.0 (IBM Corp., Ar-
monk, NY, USA) to perform statistical analysis.
Ethical Statement
This study was conducted in accordance with the Declara-
tion of Helsinki (2013 version) and approved by the Joint 
Clinical Research Ethics Committee of the Chinese Uni-
versity of Hong Kong and Hospital Authority New Terri-
tory East Cluster. All clinical data were anonymized by the 
CDARS, and all potential patient identifiers were removed 
upon return of database searches.
Results
Disease Burden, Incidence, and Clinical Outcomes
We identified 15,753 CDIs during 2006−2014. These infec-
tions included 14,402 (91.4%) healthcare-associated and 
817 (5.1%) community-associated infections. The remain-
ing 534 infections were indeterminate. The median age of 
case-patients was 78 (range 64–86) years, and there were 
more women (51.6%) in the entire cohort. The diagnostic 
test-adjusted incidence increased significantly from 15.41 
cases/100,000 persons in 2006 to 36.31 cases/100,000 per-
sons in 2014 (p<0.01 by χ2 test for trend). We observed 
the trend of increase across all age groups. However, the 
incidence for elderly persons (>65 years of age) increased 
by the largest margin from 12.98 cases/100,000 persons in 
2006 to 35.11 cases/100,000 persons in 2014 (Figure 1). The 
incidence of CA-CDI increased by more than 4-fold from 
0.86 cases/100,000 persons in 2006 to 2.96 cases/100,000 
persons in 2014. Incidence of HA-CDI increased annually 
by an average of 26%, and incidence of CA-CDI increased 
annually by an average of 29% (Table 1). 
The overall 30-day mortality rate was 22.5%. The dis-
ease recurrence rate was 7.8% at 60 days after completion 
of initial CDI treatment. A total of 30.2% of the patients 
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lived in a home for the elderly, and most (79.4%) patients 
had visited a healthcare facility <4 weeks before disease 
onset. Most (>75.6%) patients had taken an antimicrobial 
drug known to be associated with medium to high risk for 
CDI before disease onset (14,15). A total of 47.8% had 
taken a proton-pump inhibitor, and 47.3% had taken a his-
tamine-2 antagonist (Table 2).
Clinical Characteristics and Outcomes of  
HA-CDI and CA-CDI
We studied demographic and clinical characteristics in CDI 
patients of the 2 epidemiologic categories. Charlson comor-
bidity scores and proportions with severe CDI were similar 
between the 2 groups. Median ages (IQR) were 79 (65–86) 
years for patients with HA-CDI and 75 (57–85) years for 
patients with CA-CDI. For the CA-CDI group, male sex 
(41.2%), residence in a home for the elderly (24.9%), and 
exposure to high-risk antimicrobial drugs (36.6%) were 
less common than for HA-CDI group. The 30-day all-
cause mortality rates were 9.8% for the CA-CDI group and 
23.2% for the HA-CDI group, and the 60-day recurrence 
rates were 3.0% for the CA-CDI group and 8.0% for the 
HA-CDI group. However, a higher proportion of patients 
with CA-CDI than patients with HA-CDI had inflamma-
tory bowel diseases (4.4% vs. 0.4%) (Table 2).
Risk Factors for Death and Recurrence
Logistic regression modeling suggested that advanced age 
(adjusted odds ratio [OR] 5.04, 95% CI 3.88–6.55), non-
metastatic tumor (adjusted OR 1.60, 95% CI 1.45–1.75), 
and healthcare-associated infection (adjusted OR 1.55, 
95% CI 1.12–1.44) were the major predictors for death in 
30 days. Other risk factors, including residence in a home 
for the elderly, exposure to high-risk antimicrobial drugs, 
and having renal diseases, each increased the risk for CDI 
by 39% to 47% (Table 3).
Figure 1. Clostridium difficile infections in adults, Hong Kong, China, 2006–2014. A) Crude incidence of healthcare-associated and 
community-associated C. difficile infections increased significantly (p<0.001 by χ2 test for trend). B) Incidence of infections, by age group.
 
Table 1. Estimated crude incidence of Clostridium difficile infections, Hong Kong, China, by epidemiologic category, 2006–2014* 
Year 
Adult 
population† 
No. (%) CDI‡ 
Incidence/100,000 persons 
Crude Adjusted§ 
Overall HA-CDI CA-CDI Overall HA-CDI CA-CDI Overall HA-CDI CA-CDI 
2006 5,571,096 903 836 (92.58) 48 (5.32) 16.21 15.01 0.86 15.41 14.26 0.82 
2007 5,553,789 849 786 (92.58) 35 (4.12) 15.29 14.15 0.63 14.35 13.29 0.59 
2008 5,635,881 953 888 (93.18) 41 (4.30) 16.91 15.76 0.73 15.53 14.68 0.67 
2009 5,711,689 1,156 1,082 (93.60) 42 (3.63) 20.24 18.94 0.74 23.11 21.63 0.84 
2010 5,788,704 1,389 1,284 (92.44) 62 (4.46) 24.00 22.18 1.07 20.77 19.19 0.93 
2011 5,865,870 2,079 1,890 (90.91) 105 (5.05) 35.44 32.22 1.79 23.40 21.28 1.18 
2012 5,943,512 2,576 2,341 (90.88) 141 (5.47) 43.34 39.39 2.37 33.32 30.28 1.82 
2013 6,014,771 2,844 2,594 (91.21) 163 (5.73) 47.28 43.13 2.71 34.71 31.66 1.99 
2014 6,085,892 3,004 2,701 (89.91) 180 (5.99) 49.36 44.38 2.96 36.31 39.90 2.18 
Overall¶ NA NA NA NA 29.46 
(15.85–
43.07)# 
26.94 
(14.79–
39.09) 
1.51 
(0.63–
2.39) 
24.10 
(17.42–
30.77) 
22.91 
(15.86–
29.96) 
1.22 
(0.76–
1.69) 
*CDI, Clostridium difficile infection; CA-CDI, community-associated CDI; HA-CDI, healthcare-associated CDI; NA, not applicable. 
†Midyear population >18 years of age reported by the Census and Statistics Department of Hong Kong. 
‡There were 534 indeterminate cases according to criteria of Cohen et al (13): n = 19 (2006); n = 28 (2007); n = 24 (2008); n = 32 (2009); n = 43 (2010); n 
= 84 (2011); n = 94 (2012); n = 87 (2013); n = 123 (2014). 
§Overall incidence adjusted for diagnostic method use, assuming equal sensitivity across tests. The 2010 cohort was used as the reference population. 
¶Values in parentheses in this row are 95% CIs. 
#p<0.01 by 2 test for trend. 
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When we considered the 60-day disease recurrence, 
Cox regression analysis showed that the use of a toxin 
detection assay (adjusted hazard ratio 1.79, 95% CI 1.53–
2.11) and healthcare-associated infection (adjusted hazard 
ratio 1.52, 95% CI 1.06–2.20) were the major predictors. 
Other risk factors included severe CDI and exposure to 
high-risk antimicrobial drugs (Table 4). When compared 
with incident cases, we found that the odds for recurrence 
among the first recurrent cases was 1.57 (95% CI 1.35–
1.82). These odds increased to 2.10 (95% CI 1.62–2.74) 
after 2 recurrent episodes, and further increased by ≈10% 
to 2.22 (95% CI 1.38–3.57) after the third episode.
Secular Changes in Mortality and Recurrence Rates
During 2006−2014, the crude 30-day all-cause mortality 
rate decreased slightly from 25.7% to 21.0% (OR 0.77, 
95% CI 0.64–0.92; p = 0.01). Healthcare-associated case-
patients in the 2014 cohort had an ≈20% reduced risk for 
death (OR 0.80, 95% CI 0.67–0.97; p = 0.02). The reduction 
was more apparent among the community-associated case-
patients (OR 0.30, 95% CI 0.17–0.51; p<0.01). Despite the 
decreasing mortality rate, the recurrence rate increased sig-
nificantly from 5.7% in 2006 to 9.1% in 2014 (p<0.01 by χ2 
test for trend) (Figure 2, panel A). This increase represented 
an ≈70% increase in the recurrence rate (OR 1.66, 95% CI 
1.23–2.24). Further analysis suggested that the prevalence 
of severe disease, change of diagnostic test used, and expo-
sure to proton-pump inhibitor changed over time (Table 5). 
We observed the same increasing trend for CA-CDI (2.5% 
vs. 5.7%) and HA-CDI (5.7% vs. 9.5%) during 2006−2014. 
Most recurrences occurred within 60 days after completion 
of initial treatment (Figure 2, panel B).
 
Table 2. Characteristics of patients with Clostridium difficile infections, Hong Kong, China, 2006–2014* 
Characteristic 
No. (%) patients 
Overall, n = 15,753† HA-CDI, n = 14,402 CA-CDI, n = 817 
Age, y    
 <44 1,040 (6.6) 893 (6.2) 105 (12.9) 
 45–64  2,930 (18.6) 2,621 (18.2) 203 (24.8) 
 65–84  7,026 (44.6) 6,495 (45.1) 301 (36.9) 
 >85  4,757 (30.2) 4,393 (30.5) 208 (25.4) 
Sex    
 M 7,624 (48.4) 7,028 (48.8) 337 (41.2) 
 F 8,129 (51.6) 7,374 (51.2) 480 (58.8) 
Resident of home for elderly persons 4,757 (30.2) 4,393 (30.5) 203 (24.9) 
Severe disease 6,868 (43.6) 6,294 (43.7) 340 (41.6) 
Antimicrobial drug use‡    
 High-risk drug 10,397 (66.0) 9,822 (68.2) 299 (36.6) 
 Medium-risk drug 11,909 (75.6) 11,320 (78.6) 318 (38.9) 
 Low-risk drug 221 (1.4) 216 (1.5) 74 (1.4) 
Diagnostic test    
 Bacterial culture 4,883 (31.0) 4,421 (30.7) 259 (31.7) 
 Toxin detection  5,246 (33.3) 4,940 (34.3) 195 (23.9) 
 NAAT 5,624 (35.7) 5,041 (35.0) 363 (44.4) 
Use of proton-pump inhibitor 7,530 (47.8) 7,086 (49.2) 180 (22.0) 
Use of histamine-2 receptor antagonist 7,451 (47.3) 6,927 (48.1) 273 (33.4) 
Concurrent condition    
 Myocardial infarction 1,497 (9.5) 1,411 (9.8) 29 (3.6) 
 Cerebrovascular disease 5,183 (32.9) 4,825 (33.5) 176 (21.6) 
 Chronic lung disease 2,410 (15.3) 2,232 (15.5) 100 (12.2) 
 Diabetes mellitus  2,899 (18.4) 2,693 (18.7) 103 (12.6) 
 Renal disease 3,592 (22.8) 3,341 (23.2) 113 (13.8) 
 Nonmetastatic tumor 3,970 (25.2) 3,701 (25.7) 134 (16.4) 
 AIDS 79 (0.5) 58 (0.4) 13 (1.6) 
 Inflammatory bowel disease 95 (0.6) 58 (0.4) 36 (4.4) 
Deaths    
 During hospital stay 3,733 (23.7) 3,528 (24.5) 51 (6.2) 
 30-d all-cause 3,544 (22.5) 3,341 (23.2) 80 (9.8) 
 60-d all-cause 5,088 (32.3) 4,781 (33.2) 106 (13.0) 
Recurrence, d§    
 30 961 (6.1) 907 (6.3) 17 (2.1) 
 60 1,229 (7.8) 1,152 (8.0) 25 (3.0) 
 90 1,339(8.5) 1,267 (8.8) 28 (3.4) 
 180 1,481(9.4) 1,397 (9.7) 33 (4.0) 
*CA-CDI, community-associated C. difficile infection; CDI; HA-CDI, healthcare-associated C. difficile infection; NAAT, nucleic acid amplification test. 
†Sum of HA-CDI and CA-CDI cases might not equal number of overall CDI cases because of missing information in the registry. 
‡Antimicrobial drug use 8 weeks before diagnosis was stratified into high risk (floroquinolones, cephalosporins, and clindamycin); medium risk (penicillins, 
macrolides, and sulfonamides); and low risk (tetracyclines).  
§Defined as reappearance of symptoms after initial resolution and a positive CDI test result. 
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Discussion
Our main finding was the increasing incidence of CDI dur-
ing 2006−2014 by an adjusted rate of 21% annually for 
HA-CDI and CA-CDI in Hong Kong. This increase was 
less than the 39% annual increase in South Korea (5) but 
higher than the 24% annual increase in Australia (7). This 
difference might be partially caused by increasing clinical 
suspicion, introduction of sensitive diagnostic tests in 2010, 
an aging population, or endemicity and virulence of the C. 
difficile bacterium. Prescriptions for antimicrobial drugs in 
Hong Kong have been closely monitored, and relevant use 
guidelines are available (16). In the United Kingdom and 
Finland, introduction of antimicrobial drug stewardship 
programs has considerably reduced CDI in hospitals (2,4).
In our study, the aging population contributed to the 
temporal increase. Advanced age is a well-established risk 
factor for CDI; we observed a 2% increased risk for dis-
ease for each additional year of age (17). In our population, 
the incidence rate for elderly persons >75 years of age was 
higher than that for other age groups. In Hong Kong, the 
population is aging rapidly because of increased life expec-
tancy and reduced birthrate. According to the latest United 
Nations report, the life expectancy at birth in Hong Kong is 
the longest in the world (18). Given the predicted increase 
in elderly persons >75 years of age from 7.3% in 2014 to 
17.8% in 2041, the incidence of CDI is expected to reach 
75.86 cases/100,000 persons (19). In addition, our logistic 
regression analysis showed that mortality and recurrence 
rates were much higher in elderly patients. Thus, the inci-
dence of CDI might be expected to further increase, which 
represents a large burden on the healthcare system. Rel-
evant surveillance should be enhanced and public health 
measures should be incorporated to reduce the disease bur-
den, especially in places with an aging population.
Stratification of cases into epidemiologic categories 
showed that healthcare-associated infections contributed 
>90% of all incident cases detected. This contribution was 
considerably higher than those in some studies reporting 
up to 70% cases of healthcare origin (1,2,7). However, our 
rate was comparable to rates reported in 2 other studies in 
Asia (10,20). These findings highlight possible discrepant 
epidemiologic etiologies of the infection at different loca-
tions (21). Recent emergence of C. difficile ribotype 002 in 
the region may also account for the discrepancy (15,22,23). 
This common circulating ribotype has a greater propensity 
to sporulate and produce toxins. These spores and toxin 
 
Table 3. Association between 30-day all-cause deaths and potential independent variables for patients with Clostridium difficile 
infections, Hong Kong, China, 2006–2014* 
Variable 
Univariate analysis Multivariate analysis† 
 OR (95% CI) p value  Adjusted OR (95% CI) p value 
Age, y       
 <44 NA 1.0 NA NA 1.0 NA 
 4564 0.38 1.46 (1.34–1.58) <0.01 0.39 1.48 (1.35–1.62) <0.01 
 6584 1.02 2.77 (2.45–3.14) <0.01 0.99 2.69 (2.34–3.08) <0.01 
 >85 1.77 5.87 (4.57–7.56) <0.01 1.62 5.04 (3.88–6.55) <0.01 
Male sex 0.10 1.11 (1.03–1.19) 0.01 0.17 1.18 (1.09–1.28) <0.01 
Resident of home for elderly persons 0.55 1.73 (1.59–1.87)  <0.01 0.33 1.39 (1.27–1.52) <0.01 
Severe disease‡ 0.01 0.99 (0.92–1.08) 0.94 NA NA NA 
Antimicrobial drug use§        
 High-risk drug 0.62 1.85 (1.68–2.04) <0.01 0.34 1.40 (1.26–1.56) <0.01 
 Medium-risk drug 0.17 1.18 (1.09–1.28) <0.01 0.10 1.11 (1.02–1.21) 0.02 
 Low-risk drug 0.24 1.27 (0.94–1.72) 0.12 NA NA NA 
Diagnostic test       
 Bacterial culture NA 1.0 NA NA 1.0 NA 
 Toxin detection 0.33 0.72 (0.65–0.79) <0.01 0.25 0.78 (0.71–0.86) <0.01 
 NAAT 0.13 0.88 (0.80–0.97) <0.01 -0.05 0.95 (0.86–1.05) 0.34 
Use of proton-pump inhibitor 0.37 1.44 (1.34–1.56) <0.01 0.24  1.27 (1.17–1.38) <0.01 
Use of histamine-2 receptor antagonist 0.15 1.16 (1.08–1.25) <0.01 0.11 1.12 (1.03–1.21) <0.01 
Healthcare-associated disease 0.63 1.88 (1.65–2.13) <0.01 0.44 1.55 (1.12–1.44) <0.01 
Concurrent condition       
 Myocardial infarction 0.44 1.54 (1.37–1.74) <0.01 0.24 1.27 (1.12–1.44) <0.01 
 Cerebrovascular disease 0.10 1.11 (1.02–1.20) 0.01 0.14  1.14 (1.05–1.25) <0.01 
 Chronic lung disease 0.08 1.08 (0.97–1.19) 0.16 NA NA NA 
 Diabetes mellitus  0.06 1.06 (0.96–1.17) 0.24 NA NA NA 
 Renal disease 0.31 1.36 (1.25–1.48) <0.01 0.39 1.47 (1.34–1.61) <0.01 
 Nonmetastatic tumor 0.18 1.2 (1.10–1.31) <0.01 0.47 1.60 (1.45–1.75) <0.01 
 AIDS 0.11 0.59 (0.31–1.12) 0.11 NA NA NA 
 Inflammatory bowled disease 1.39 0.25 (0.13–0.49) <0.01 0.36 0.70 (0.35–1.41) 0.32 
*NA, not applicable; NAAT, nucleic acid amplification test. 
†p = 0.74 by Hosmer-Lemeshow test. 
‡Severe disease was diagnosed according to the according to criteria of Cohen et al (13).  
§Antimicrobial drug use 8 weeks before diagnosis was stratified into high risk (floroquinolones, cephalosporins, and clindamycin); medium risk (penicillins, 
macrolides, and sulfonamides); and low risk (tetracyclines). 
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producers might facilitate bacterial dissemination in the 
hospital environment and increase the number of symp-
tomatic patients. Because data were available for tertiary 
care settings in our study, community cases might not be 
recognized unless patients became sufficiently ill for hos-
pital admission. A delay in diagnosis is rather common for 
CA-CDI (10).
Emergence of CA-CDI has been increasingly rec-
ognized. Persons with this type of infection have had no 
traditional risk factors associated with nosocomial infec-
tion. The younger age of the disease population has led 
to concern over loss of productivity and years of life lost 
(3,24). Despite the relatively low prevalence, we observed 
a higher increase of incidence for the community than that 
for healthcare settings. Risk factors for acquisition of CDI 
in the community are unclear, but bacterial, host, and envi-
ronmental factors have been suggested to play a role (25). 
Contamination of retail meats with C. difficile spores might 
represent a potential reservoir for infection of humans 
(26,27). Contact with contaminated raw meat has been rec-
ognized as a risk factor for nasal colonization with Staphy-
lococcus aureus in humans (28). Molecular typing of C. 
difficile isolates from contaminated raw meat and those 
from exposed personnel might identify a novel reservoir 
for asymptomatic carriage. Although not yet proven for 
the community, asymptomatic carriers have been shown to 
contribute to transmission of C. difficile strains in health-
care facilities (29).
The 30-day all-cause mortality rate decreased slightly 
during the study period. This finding was consistent with 
other reports in which 20%−30% reductions were detected 
(5,30). When compared with mortality rates for CA-CDI, 
mortality rates at different times were consistently higher 
in the HA-CDI group. This finding is consistent with an-
other report in which a 4-fold higher case-fatality rate for 
HA-CDI was observed (2). Consistently, logistic regres-
sion analysis suggested that healthcare-associated cases, in 
addition to advanced age, were the major risk factors for 
30-day all-cause mortality rates.
The recurrence rate for our population was consider-
ably lower than rates reported for Western countries (3,5,8). 
Although this discrepancy would require further validation, 
our data might indicate lower disease recurrence rates for 
Asia. Because various therapies other than antimicrobial 
drugs, including colectomy and fecal microbiota trans-
plant, have been considered for managing recurrent CDI 
 
Table 4. Cox proportional hazard regression analysis of potential independent variables associated with time to recurrence of 
Clostridium difficile infections, Hong Kong, China, 2006–2014* 
Variable 
Univariate analysis Multivariate analysis 
 Hazard ratio (95% CI) p value  
Adjusted hazard ratio 
(95% CI) p value 
Age, y       
 <44 NA 1.0 NA NA 1.0 NA 
 4564 0.14 1.15 (0.86–1.55) 0.34 0.01 1.00 (0.74–1.36) 0.99 
 6584 0.29 1.33 (0.01–1.75) 0.04 0.04 1.04 (0.78–1.38) 0.81 
 >85 0.41 1.50 (1.14–1.98) <0.01 0.16 1.17 (0.87–1.56) 0.29 
Male sex 0.02 0.99 (0.88–1.10) 0.79 NA NA NA 
Resident of home for elderly persons 0.02 0.98 (0.87–1.11) 0.99 NA NA NA 
Severe disease† 0.32 1.38 (1.22–1.55) <0.01 0.35 1.41 (1.26–1.59) <0.01 
Antimicrobial drug use‡       
 High-risk drug 0.49 1.55 (1.36–1.77) <0.01 0.32 1.37 (1.20–1.57) <0.01 
 Medium-risk drug 0.41 1.51 (1.33–1.72) 0.01 0.01 0.99 (0.86–1.16) 0.96 
 Low-risk drug 0.11 1.12 (0.69–1.83) 0.66 NA NA NA 
Diagnostic test       
 Bacterial culture NA 1.0 NA NA 1.0 NA 
 Toxin detection 0.69 1.89 (1.62–2.21) 0.01 0.57 1.79 (1.53–2.11) <0.01 
 NAAT 0.27 1.31 (1.12–1.52) 0.01 0.23 1.26 (1.08–1.47) <0.01 
Use of proton-pump inhibitor 0.08 1.09 (0.97–1.22) 0.16 NA NA NA 
Use of histamine-2 receptor antagonist 0.18 1.19 (1.07–1.34) 0.01 0.09 1.09 (0.97–1.22) 0.15 
Healthcare-associated disease 0.49 1.65 (1.15–2.35) 0.01 0.42 1.52 (1.06–2.20) 0.02 
Concurrent condition       
 Myocardial infarction 0.09 1.10 (0.92–1.32) 0.32 NA NA NA 
 Cerebrovascular disease 0.49 1.63 (1.46–1.82) <0.01 0.15 0.86 (0.74–0.99) 0.04 
 Chronic lung disease 0.05 0.95 (0.82–1.12) 0.56 NA NA NA 
 Diabetes mellitus  0.08 1.08 (0.94–1.24) 0.30 NA NA NA 
 Renal disease 0.05 1.05 (0.92–1.20) 0.47 NA NA NA 
 Nonmetastatic tumor 0.24 0.79 (0.69–0.90) 0.01 0.15 0.86 (0.74–0.99) 0.04 
 AIDS 0.58 0.56 (0.18–1.74) 0.32 NA NA NA 
 Inflammatory bowel disease 0.14 1.15 (0.62–2.14) 0.66 NA NA NA 
*NA, not applicable; NAAT, nucleic acid amplification test. 
†Severe disease was diagnosed according to the according to criteria of Cohen et al (13).  
‡Antimicrobial drug use 8 weeks before diagnosis was stratified into high risk (floroquinolones, cephalosporins, and clindamycin); medium risk (penicillins, 
macrolides, and sulfonamides); and low risk (tetracyclines). 
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cases, this lower recurrence rate might indicate a need to 
reconsider the risk−benefit balance when deciding which 
therapies to use. Further studies are warranted to investi-
gate differences in recurrence rates.
We also observed a major increase in recurrence rate 
over the study period. The factors accounting for this 
change were multifactorial and might include change of di-
agnostic method used over time, increasing prevalence of 
severe disease, and exposure to proton-pump inhibitors. A 
systematic review of 68 studies concluded that use of an-
timicrobial drugs after diagnosis, in addition to older age, 
were major risk factors for recurrence (31). However, in 
our study, we did not investigate exposure to antimicro-
bial drugs after diagnosis. Similarly, increased ward-level 
prescriptions for antimicrobial drugs have been shown to 
increase CDI in hospitalized patients (32).
Figure 2. Clostridium difficile infections in adults, Hong Kong, China, 2006–2014. A) Prevalence of 60-day recurrence increased 
significantly (p<0.001 by χ2 test for trend. B) Recurrence rates, which were higher for healthcare-associated infections.
 
Table 5. Temporal change in exposure prevalence for patients with Clostridium difficile infections in association with trend in 
recurrence, Hong Kong, China, 2006–2014* 
Exposure 
Period, prevalence (standardized Pearson residuals), % Absolute residual 
difference, %† p value‡ 2006–2008 2009–2011 2012–2014 
Age, y      
 <44 18.3 (0.4) 34.9 (3.0) 46.8 (2.5) 2.9 <0.01 
 45–64 17.4 (0.6) 32.5 (2.6) 50.1 (1.7) 1.1 <0.01 
 65–84 19.2 (2.7) 28.9 (1.4) 51.9 (0.5) 3.2 <0.01 
 >85 16.1 (3.0) 28.4 (1.8) 55.5 (3.1) 6.1 <0.01 
Male sex 48.6 (0.1) 48.5 (0.0) 48.4 (0.1) 0.2 0.97 
Resident of home for elderly persons 27.6 (2.6) 29.5 (1.0) 31.6 (2.3) 4.9 <0.01 
Severe disease 16.9 (10.5) 32.6 (2.6) 50.5 (6.7) 17.2 <0.01 
Antimicrobial drug use§      
 High-risk drug 18.5 (1.5) 28.4 (2.7) 53.1 (1.2) 0.3 0.65 
 Medium-risk drug 17.4 (1.1) 28.1 (3.6) 54.5 (3.3) 4.4 <0.01 
 Low-risk drug 12.6 (1.9) 19.3 (2.9) 152 (3.3) 5.2 <0.01 
Diagnostic test      
 Bacterial culture 18.9 (1.7) 29.0 (1.0) 52.0 (0.3) 2 <0.01 
 Toxin detection 36.0 (31.1) 35.0 (6.9) 28.9 (23.4) 54.5 <0.01 
 NAAT 0 (31.7) 25.7 (5.7) 74.3 (22.9) 54.6 <0.01 
Use of proton-pump inhibitor 35.8 (9.0) 40.7 (6.6) 55.2 (10.3) 19.3 <0.01 
Use of histamine-2 receptor antagonist 54.7 (6.0) 46.1 (0.9) 44.9 (2.9) 8.9 <0.01 
Healthcare-associated disease 18.1 (0.7) 30.0 (0.5) 51.9 (0.7) 1.4 <0.01 
Concurrent condition      
 Myocardial infarction 5.3 (7.2) 7.9 (3.4) 11.7 (6.8) 14 <0.001 
 Cerebrovascular disease accident 28.8 (3.4) 32.8 (0.5) 33.5 (1.7) 5.1 <0.01 
 Chronic lung disease 12.4 (3.6) 14.5 (1.0) 16.3 (2.9) 6.5 <0.01 
 Diabetes mellitus 20.5 (2.6) 19.0 (1.0) 17.3 (2.3) 4.9 <0.01 
 Renal disease 18.4 (4.8) 22.5 (0.2) 24.3 (3.1) 7.9 <0.01 
 Nonmetastatic tumor 21.7 (3.7) 27.1 (2.6) 25.2 (0.2) 3.9 0.01 
 AIDS 0.5 (0.2) 0.6 (0.8) 0.4 (0.7) 0.9 0.55 
 Inflammatory bowel disease 0.5 (2.0) 0.7 (1.2) 1.1 (2.2) 4.4 0.01 
*NAAT, nucleic acid amplification test. 
†Absolute difference between standardized Pearson residuals in 2012–2014 and 2006–2008. 
‡By 2 test for trend. 
§Antimicrobial drug use 8 weeks before diagnosis was stratified into high risk (floroquinolones, cephalosporins, and clindamycin); medium risk (penicillins, 
macrolides, and sulfonamides); and low risk (tetracyclines). 
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Our study was strengthened by use of a large territory-
wide population. Because public hospitals provide >90% 
of the entire inpatient service in Hong Kong, our study was 
representative of the region. Our study also investigated the 
temporal trend of burden of CDI. All data, including demo-
graphics, laboratory findings, and clinical records, were ob-
jectively recorded in a database. Thus, there was no cause 
for concern regarding recall bias.
Nevertheless, our study had some limitations. First, the 
study relied on inpatient data for which cases diagnosed in 
outpatient clinics might have been missed. This limitation 
might lead to underestimation of disease burden, particu-
larly for community-associated case-patients with milder 
disease, who have been managed as outpatients without 
the need for hospitalization. This limitation might have 
also skewed clinical characteristics and outcomes for this 
group, although all patients with severe cases requiring 
hospitalization would have been represented in our data.
Second, because of lack of coding, our database was 
not able to capture fecal microbiota transplants as a novel 
therapy for recurrent CDI. Nevertheless, because of opera-
tional and logistic difficulties, fecal microbiota transplant 
has been used sparsely for selected patients (33). This pro-
cedure was unlikely to have caused any major changes in 
overall disease epidemiology. 
Third, we did not include repeated exposure to anti-
microbial drugs after initial CDI diagnosis in our database. 
This limitation might potentially serve as a major factor for 
subsequent disease recurrence.
Fourth, as with other retrospective studies (1,2,7,34,35), 
the diagnosis of CDI in our study was based on differ-
ent laboratory methods, including bacteriological culture, 
toxin detection, and molecular assays. Given the variable 
sensitivity and specificity of these tests, this limitation 
could have biased estimation of disease incidence. Cases 
of pseudomembranous colitis diagnosed only by histologic 
analysis might have been missed. Thus, the incidence of 
CDI might be underestimated.
In conclusion, the incidence of CDI is increasing at a 
rapid rate in Hong Kong. Further surveillance of this infec-
tion in this area is urgently needed.
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